Can a single antibody help people with HIV pause their pills?

NCT ID NCT04860323

Completed Knowledge-focused Sponsor: HIV Vaccine Trials Network Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether an experimental antibody called VRC01 could help people with HIV control the virus after they stop taking their daily HIV medication. Thirteen people who had received VRC01 or a placebo in an earlier study and later got HIV took part. They paused their HIV drugs under close monitoring to see how long their immune system could keep the virus in check.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VRC01 (an experimental antibody)
What this could lead to: If successful, this could point toward ways to help some people with HIV control the virus without daily medication.
What could go wrong: This is a very small, early study with only 13 participants. It is designed to gather information, not to prove a treatment works. Stopping HIV medication carries risks, including virus rebound.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Locations

Blantyre CRS

Blantyre, Malawi
CAPRISA eThekwini CRS

Durban, South Africa
Gaborone CRS

Gaborone, Botswana
Kliptown Soweto CRS

Johannesburg, South Africa
Malawi CRS

Lilongwe, Malawi
Milton Park CRS

Harare, Zimbabwe
Rustenburg CRS

Rustenburg, South Africa
Seke South CRS

Harare, Zimbabwe
Spilhaus CRS

Harare, Zimbabwe
Vulindlela CRS

Durban, South Africa
Ward 21 CRS

Johannesburg, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.